Ellevest Inc’s Blueprint Medicines BPMC Stock Holding History

Ellevest Inc’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$90	–	542
2023 Q1	$90	Buy	+2	New	+$90	﹤0.01%	1807

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ellevest Inc's BPMC Position: Q2 2023 in Review

Ellevest Inc sold out of Blueprint Medicines (BPMC) in Q2 2023, closing a stake of 2 shares — an estimated $90 sold.

Ellevest Inc first reported a position in BPMC in Q1 2023 and held it in 1 quarter. The position peaked at $90 in Q1 2023. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

Ellevest Inc reported no remaining Blueprint Medicines position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 2 Blueprint Medicines shares in Q2 2023, an estimated $90.
Ellevest Inc first reported a position in Blueprint Medicines in Q1 2023 and held it in 1 quarter.
Ellevest Inc's Blueprint Medicines position peaked at $90 in Q1 2023.
222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.